Welch & Forbes Has Lowered Sherwin Williams Co (SHW) Position By $375,900; Clovis Oncology (CLVS) Has 1.44 Sentiment

February 21, 2018 - By Linda Rogers

Welch & Forbes Llc decreased Sherwin Williams Co (SHW) stake by 5.98% reported in 2017Q3 SEC filing. Welch & Forbes Llc sold 1,050 shares as Sherwin Williams Co (SHW)’s stock rose 6.75%. The Welch & Forbes Llc holds 16,496 shares with $5.91 million value, down from 17,546 last quarter. Sherwin Williams Co now has $37.56B valuation. The stock increased 1.25% or $4.95 during the last trading session, reaching $401.62. About 244,463 shares traded. The Sherwin-Williams Company (NYSE:SHW) has risen 15.27% since February 21, 2017 and is uptrending. It has underperformed by 1.43% the S&P500.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.74 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

The stock increased 4.06% or $2.18 during the last trading session, reaching $55.89. About 434,795 shares traded. Clovis Oncology, Inc. (CLVS) has risen 282.71% since February 21, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Ratings analysis reveals 67% of Clovis Oncology’s analysts are positive. Out of 9 Wall Street analysts rating Clovis Oncology, 6 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $15.0 while the high is $74.0. The stock’s average target of $42.67 is -23.65% below today’s ($55.89) share price. CLVS was included in 9 notes of analysts from August 24, 2016. The stock has “Overweight” rating by Piper Jaffray on Thursday, January 26. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Neutral” rating given on Wednesday, August 24 by Mizuho. The company was upgraded on Wednesday, September 21 by Credit Suisse. Stifel Nicolaus maintained Clovis Oncology, Inc. (NASDAQ:CLVS) rating on Wednesday, September 21. Stifel Nicolaus has “Buy” rating and $45.0 target. The rating was initiated by Morgan Stanley with “Overweight” on Friday, January 13. SunTrust maintained it with “Buy” rating and $50.0 target in Friday, September 23 report. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Sell” rating given on Tuesday, October 25 by Chardan Capital Markets. As per Friday, January 27, the company rating was initiated by Bank of America. WallachBeth Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, December 21 with “Hold” rating.

Palo Alto Investors Llc holds 11.56% of its portfolio in Clovis Oncology, Inc. for 3.33 million shares. Venbio Select Advisor Llc owns 785,700 shares or 5.02% of their US portfolio. Moreover, Redmile Group Llc has 4.05% invested in the company for 996,610 shares. The New York-based Iguana Healthcare Management Llc has invested 3.68% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 251,699 shares.

Since January 1, 0001, it had 0 insider buys, and 6 selling transactions for $1.29 million activity.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on February, 26 after the close. They expect $-1.28 earnings per share, up 30.05% or $0.55 from last year’s $-1.83 per share. After $-1.24 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 3.23% negative EPS growth.

Analysts await The Sherwin-Williams Company (NYSE:SHW) to report earnings on April, 19. They expect $3.13 EPS, up 37.89% or $0.86 from last year’s $2.27 per share. SHW’s profit will be $292.70M for 32.08 P/E if the $3.13 EPS becomes a reality. After $2.95 actual EPS reported by The Sherwin-Williams Company for the previous quarter, Wall Street now forecasts 6.10% EPS growth.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.01, from 1.22 in 2017Q2. It is negative, as 60 investors sold SHW shares while 210 reduced holdings. 80 funds opened positions while 247 raised stakes. 69.43 million shares or 2.00% more from 68.06 million shares in 2017Q2 were reported. Moreover, Wealthtrust has 0% invested in The Sherwin-Williams Company (NYSE:SHW). Palisade Asset Mngmt Ltd stated it has 662 shares or 0.04% of all its holdings. Commonwealth Of Pennsylvania School Empls Retrmt has invested 0.04% of its portfolio in The Sherwin-Williams Company (NYSE:SHW). Haverford Co has 0.05% invested in The Sherwin-Williams Company (NYSE:SHW). Kbc Nv holds 16,837 shares or 0.05% of its portfolio. Oskie Capital Mngmt accumulated 8,300 shares or 3.38% of the stock. Compton Cap Mngmt Ri owns 700 shares. Invesco Ltd reported 0.14% in The Sherwin-Williams Company (NYSE:SHW). Chilton Limited Com stated it has 472,891 shares. Minnesota-based Bremer National Association has invested 0.15% in The Sherwin-Williams Company (NYSE:SHW). Sei Com accumulated 74,846 shares or 0.1% of the stock. Tiverton Asset Management Limited Liability Corp owns 956 shares. Cantab Cap Prns Llp invested 0.06% in The Sherwin-Williams Company (NYSE:SHW). Old Commercial Bank In invested 0.4% of its portfolio in The Sherwin-Williams Company (NYSE:SHW). Lombard Odier Asset Management (Europe) Limited has invested 0.02% in The Sherwin-Williams Company (NYSE:SHW).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: